Associate Professor Dipti Talaulikar

MBBS, PhD, FRACP, FRCPA, Grad Cert HE
Staff Specialist, Canberra Hospital
Associate Professor, ANU Medical School

I am a physician scientist working full time as staff specialist in the department of Haematology at Canberra Hospital. I obtained my fellowships for RACP and RCPA in 2006-07 and completed a PhD at ANU (2006-2009). I have a Specialist Certificate in Clinical Research from Melbourne University.

I effectively set up the Haematology Research Tissue Bank, a repository of peripheral blood, bone marrow and primary tissue samples from patients with haematological and related disorders, and have been managing this for 6 years.

Over the last 2 years I have gradually built a team of staff and collaborators to support a lymphoma research program. Our Haematology Translational Research Unit at Canberra Hospital supports medical and research students.

Specialisation

  • Haematology
  • Pathology

Research interests

The Haematology Translational Research Unit at the Canberra Hospital is mainly involved with translational research projects in lymphoproliferative disorders including lymphoma and myeloma. Our particular areas of interest lie in

1. determining the cellular origin of lymphoma using a combination of sophisticated flow cytometry and cell sorting, genotyping and ultra deep sequencing techniques,

2. etsablishing links between autoimmunity and lymphoma and

3. determining mechanisms of spread of lymphoproliferative disorders to extranodal tissues especially the bone marrow.

Most of our projects involve work on archived human tissue samples stored at the Haematology Research Tissue Bank.

  • Castillo, J, Itchaki, G, Paludo, J et al. 2019, 'Ibrutinib for the treatment of Bing-Neel syndrome: A multicenter study', Blood, vol. 133, no. 4, pp. 299-305.
  • Vari, F, Arpon, D, Keane, C et al. 2018, 'Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL', Blood, vol. 131, no. 16, pp. 1809-1819.
  • Keane, C, Tobin, J, Talaulikar, D et al. 2018, 'A high LDH to absolute lymphocyte count ratio in patients with DLBCL predicts for a poor intratumoral immune response and inferior survival', Oncotarget, vol. 9, no. 34, pp. 23620-23627.
  • Talaulikar, D, Lim, J, Wang, J et al 2017, 'Plasma cells arise from differentiation of clonal lymphocytes and secrete IGM in Waldenstrom Macroglobulinemia', 22nd Congress of the European Hematology Association, ed. Jan Cools (Leuven), Ferrata Storti Foundation, Italy, pp. Volume: 102, Supplement 2, pages 569-570.
  • El-Ayoubi, A, Wang, J, Hein, N et al 2017, 'Role of plasma cells in Waldenström macroglobulinaemia', Pathology, vol. 49, no. 4, pp. 337-345pp.
  • Keane, C, Gould, C, Jones, K et al. 2017, 'The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma', Clinical Cancer Research, vol. 23, no. 7, pp. 1820-1828.
  • Talaulikar, D, Tam, C, Joshua, D et al. 2017, 'Treatment of patients with Waldenstr?m macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group', Internal Medicine Journal, vol. 47, no. 1, pp. 35-49.
  • Talaulikar, D, Tam, C, Joshua, D et al. 2017, 'Treatment of patients with Waldenstr?m macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group', Internal Medicine Journal, vol. 47, no. 1, pp. 35-49.
  • Lee, O, Horvath, N, Lee, C et al. 2017, 'Bisphosphonate guidelines for treatment and prevention of myeloma bone disease', Internal Medicine Journal, vol. 47, no. 8, pp. 938-951.
  • Andrews, D, Jeelall, Y, Talaulikar, D et al 2016, 'DeepSNVMiner: A sequence analysis tool to detect emergent, rare mutations in subsets of cell populations', PeerJ, vol. 4, no. 5, pp. -.
  • Petvises, S, Talaulikar, D & O'Neill, H 2016, 'Delineation of a novel dendritic-like subset in human spleen', Cellular and Molecular Immunology, vol. 13, no. 4, pp. 443-450.
  • Le Cao, K, Keane, C, Han, E et al. 2015, 'Improving conventional prognosticators in diffuse large B cell lymphoma using marker ratios', Big Data and Healthcare Analytics 2015, BigData-HISA 2015, ed. K. Barbuto, L. Schaper, K. Vespoor, CEUR-WS.ORG, TBC, pp. -.
  • Keane, C, Vari, F, Hertzberg, M et al. 2015, 'Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: A population-based study', The Lancet Haematology, vol. 2, no. 10, pp. E445-E455.
  • Keane, C, Vari, F, Hertzberg, M et al. 2015, 'Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: A population-based study', The Lancet Haematology, vol. 2, no. 10, pp. E445-E455.
  • Quach, H, Joshua, D, Ho, J et al 2015, 'Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: Position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group', Internal Medicine Journal, vol. 45, no. 1, pp. 94-105.
  • Weber, N, Mollee, P, Augustson, B et al 2015, 'Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group', Internal Medicine Journal, vol. 45, no. 4, pp. 371-382.
  • Quach, H, Joshua, D, Ho, J et al 2015, 'Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: Position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group', Internal Medicine Journal, vol. 45, no. 3, pp. 335-343.
  • Subramaniam, K, Yeung, D, Grimpen, F et al 2014, 'Hepatosplenic T-cell lymphoma, immunosuppressive agents and biologicals: what are the risks?', Internal Medicine Journal, vol. 44, no. 3, pp. 287-290.
  • Eslick, R & Talaulikar, D 2013, 'Multiple myeloma: from diagnosis to treatment', Australian Family Physician, vol. 42, no. 10, pp. 684-688.
  • Phillips, D, Talaulikar, D, Hawkins, C et al 2013, 'Utilisation of sFLC assays - how well do we comply with guidelines?', International Journal of Laboratory Hematology, vol. 35, no. 2, pp. 200-210.
  • Chen, T, McDonald, A, Shadbolt, F et al 2012, 'Precision of Histological Bone Marrow Staging in Follicular Lymphoma and Diffuse Large B-cell Lymphoma', Clinical and Investigative Medicine, vol. 35, no. 6, pp. E358-E364.
  • McNiven, M & Talaulikar, D 2012, 'Establishment of a conversion factor for the Cepheid GeneXpert BCR-ABL assay', Pathology, vol. 44, no. 1, pp. 55-57.
  • Talaulikar, D, Tridgell, D, Leong, D et al 2010, 'Novel therapeutic option for orbital atypical lymphoid hyperplasia', Clinical and Experimental Ophthalmology, vol. 38, no. 9, pp. 892-894.
  • Talaulikar, D, Shadbolt, F, Dahlstrom, J et al 2009, 'Routine use of ancillary investigations in staging diffuse large B-cell lymphoma improves the International Prognostic Index (IPI)', Journal of Hematology and Oncology, vol. 2, no. 49, p. 36.
  • Talaulikar, D & Dahlstrom, J 2009, 'Staging bone marrow in diffuse large B-cell lymphoma: the role of ancillary investigations', Pathology, vol. 41, no. 3, pp. 214-222.
  • Talaulikar, D, Dahlstrom, J, Shadbolt, F et al 2008, 'Role of Immunohistochemistry in staging diffuse large B-cell Lymphoma (DLBCL)', Journal of Histochemistry and Cytochemistry, vol. 56, no. 10, pp. 893-900.
  • Talaulikar, D, Shadbolt, F, McNiven, M et al 2008, 'DNA amplification from formalin-fixed decalcified paraffin-embedded bone marrow trephine specimens: does the duration of storage matter?', Pathology, vol. 40, no. 7, pp. 702-706.
  • Talaulikar, D, Gray, J, Shadbolt, F et al 2008, 'A comparative study of the quality of DNA obtained from fresh frozen and formalin-fixed decalcified paraffin-embedded bone marrow trephine biopsy specimens using two different methods', Journal of Clinical Pathology, vol. 61, pp. 119-123.
  • Talaulikar, D, Choudhury, A, Shadbolt, F et al 2008, 'Lymphocytopenia as a Prognostic Marker for Diffuse Large B Cell Lymphoma', Leukemia & Lymphoma, vol. 49, no. 5, pp. 959-964.
  • Talaulikar, D, Sachse-Akerlind, G & Potter, J 2008, 'Bench work and clinical relevance: a new strategy in pathology education', Pathology, vol. 40, no. 7, pp. 707-710.
  • Talaulikar, D, Shadbolt, F, Bell, J et al 2008, 'Clinical role of flow cytometry in redefining bone marrow involvement in diffuse large B-cell lymphoma (DLBCL) - a new perspective', Histopathology, vol. 52, pp. 340-347.
  • Talaulikar, D, Falk, M, Talaulikar, G et al 2007, 'Immune Thrombocytopenia after Renal Transplantation for IgA Nephropathy', Acta Haematologica, vol. 117, pp. 65-67.
  • Talaulikar, D, Dahlstrom, J, Shadbolt, F et al 2007, 'Occult bone marrow involvement in patients with diffuse large B-cell lymphoma: results of a pilot study', Pathology, vol. 39, no. 6, pp. 580-585.
  • Talaulikar, D, Shadbolt, F, McDonald, A et al 2006, 'Health-related quality of life in chronic coagulation disorders', Haemophilia, vol. 12, no. 6, pp. 633-642.

Supervised students